Comparison of Denosumab Alone Versus Teriparatide Followed by Denosumab to Prevent Osteoporotic Fractures in Patients with New Fractures
Led by Peking Union Medical College Hospital · Updated on 2026-01-12
2478
Participants Needed
58
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with osteoporotic fractures to find better prevention and treatment methods for refractures. This project involves registering patients for follow-up studies to collect epidemiological data and conducting prospective treatment studies. It aims to explore effective treatment strategies through randomized controlled trials and to develop warning models using biomarkers and new imaging technologies to predict osteoporotic refractures.
Participants receive either denosumab alone or a sequential treatment starting with teriparatide followed by denosumab. Denosumab is given as a 60mg subcutaneous injection every six months for 24 months. Teriparatide is administered as a daily 20ug subcutaneous injection for either 6 or 12 months before switching to denosumab, which continues until the 24th month. These treatment plans are part of a multicenter randomized controlled trial.
During the study, participants will be monitored for new vertebral fractures and changes in bone mineral density BMD at the lumbar spine, total hip, and femoral neck over 12 and 24 months. Blood tests will measure biomarkers related to bone turnover at several time points. Researchers will also track patients adherence to treatment and assess cost-effectiveness. Follow-up includes evaluation of new fractures at various sites and safety monitoring throughout the 24-month treatment period.
CONDITIONS
Brief Title
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
Research Team
W
Weibo Xia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
New fractures at other sites or total hip/neck of femur or L1-L4 T-value less than -1.0
Men or postmenopausal women
Age between 45 and 90 years old
Ability to move independently
You will not qualify if you...
Bone metabolic diseases other than osteoporosis, such as osteogenesis imperfecta, Paget's disease, osteomalacia, Cushing's syndrome, or hyperprolactinemia
Primary hyperparathyroidism or hypothyroidism
Current or past osteomyelitis or necrosis of the jaw
Kidney function with GFR less than 30 ml/min/1.73m2
Active infection requiring systemic treatment
Use of intravenous bisphosphonate, fluoride, or strontium for osteoporosis within 2 years
Use of teriparatide or denosumab for osteoporosis within 6 months
Use of glucocorticoids equivalent to more than 5 mg/day prednisone for over 10 days within 6 weeks
Oral bisphosphonate use within one year unless cumulative use is 1 month or less
Malignant tumors or bone metastases within 5 years, except cured tumors
Hypocalcemia or hypercalcemia
Unexplained high alkaline phosphatase
Severe vitamin D deficiency (25OHD less than 10 ng/mL)
Previous external radiation or radiation therapy with bone implants
Uncontrolled heart failure, high blood sugar (HbA1c > 8.5%), or severe arrhythmias
Planned pregnancy or lactation during the study
Allergy to teriparatide or denosumab
Current participation in other drug clinical trials
Any condition making the subject unsuitable for this study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 24 months
Participants receive treatment with either Denosumab alone or sequential Teriparatide followed by Denosumab to reduce osteoporotic fracture risk.
Denosumab injections every 6 months; Teriparatide injections once daily for 6 to 12 months for those in the sequential treatment group
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing Vertebroplasty and Sham Treatment for Pain Relief and Cost in Osteoporotic Vertebral Compression Fractures in Patients 50 and Older
RESTORE Study to Reduce Future Fragility Fractures and Improve Outcomes in Adults 50 and Older
Safety and Performance Study of TEKNIMED Spine Bone Cements and Injection Systems
Used in Vertebroplasty, Kyphoplasty, and Pedicular Screw Augmentation Procedures
Comparison of Denosumab Alone Versus Teriparatide Followed by Denosumab to Prevent Osteoporotic Fractures in Patients with New Fractures
International Study on Using the Osteoporotic Fracture Classification Score to Guide Treatment Decisions for Thoracolumbar Osteoporotic Fractures
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy of sequential denosumab after teriparatide for 6 months compared with denosumab monotherapy in reducing risk of osteoporotic fractures in patients with new fractures: a multicentre randomised controlled trial (STAND study) protocol.